Latest From Exelixis Inc.
Bristol Myers Squibb brought in $500m from customers that overbought in case of drug shortages, but first quarter sales still grew 8% excluding those purchases and BMS projects growth through 2021.
Positive new top-line Phase III results look set to strengthen Opdivo combination therapy in first-line kidney cancer through an improved toxicity profile.
The cost-effectiveness of combination therapies for untreated advanced renal cell carcinoma therapies comes under the spotlight as England's HTA body rejects an immunotherapy/kinase inhibitor combination in draft guidance.
The company believes the PD-1 inhibitor’s recent declines will be reversed through new indications, providing revenue growth along with other new products by the time Revlimid faces generics in 2022.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Exelixis Inc.
- Senior Management
Michael M Morrissey, PhD, Pres. & CEO
Christopher J Senner, EVP, CFO
Peter Lamb, PhD, EVP, Scientific Strategy & CSO
Gisela M Schwab, MD, Pres., Prod. Dev. & CMO
Dana T Aftab, PhD, EVP, Bus. Operations
- Contact Info
Phone: (650) 837-7000
1851 Harbor Bay Parkway
Alameda, CA 94502